PR Newswire07.17.19
Candela Corporation, a global aesthetic device company and the exclusive licensee of certain patents of General Hospital Corporation, d/b/a Massachusetts General Hospital, Lumenis Ltd., a global leader in the field of minimally-invasive clinical solutions for the aesthetic, surgical, and ophthalmic markets, and its subsidiary, Pollogen Ltd., have entered into a mutual settlement agreement and sublicense ending the patent disputes between the companies. While terms of the settlement and sublicense agreements are confidential, Lumenis and Pollogen will continue to actively market and develop their fractional RF micro-needle product line, including the Legend and Divine family of products.
